ArticleCirculation research2016
Circulating Progenitor Cells Identify Peripheral Arterial Disease in Patients With Coronary Artery Disease.
Article in Circulation research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 49 citations in OpenAlex.
- The impact of patient sex on the response to intramyocardial mesenchymal stem cell administration in patients with non-ischaemic dilated cardiomyopathy.Cardiovascular research · 2020Trial
- Exhaustion of the bone marrow progenitor cell reserve is associated with major events in severe limb ischemia.Angiogenesis · 2019Trial
- Inflammation-modulating agents in chronic limb-threatening ischemia: a narrative review of therapeutic potential and future directions.Annals of medicine and surgery (2012) · 2026Article
- A narrative review of recent literature of circulating biomarkers of abdominal aortic aneurysm.JVS-vascular science · 2026Review
- Hypercholesterolemia and inflammation-Cooperative cardiovascular risk factors.European journal of clinical investigation · 2025Review
- Circulating Progenitor Cells and Coronary Collaterals in Chronic Total Occlusion.International journal of cardiology · 2024Article
- Narrative Review of Biological Markers in Chronic Limb-Threatening Ischemia.Biomedicines · 2024Review
- Article
- Endothelial progenitor cells as biomarkers of diabetes-related cardiovascular complications.Stem cell research & therapy · 2023Review
- A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects.Cell reports. Medicine · 2023Article
- Toward Blood-Based Precision Medicine: Identifying Age-Sex-Specific Vascular Biomarker Quantities on Circulating Vascular Cells.Cellular and molecular bioengineering · 2023Article
- Circulating progenitor cells and outcomes in patients with coronary artery disease.International journal of cardiology · 2023Article
- Review
- The association between baseline circulating progenitor cells and vascular function: The role of aging and risk factors.Vascular medicine (London, England) · 2022Article
- Glycaemic Control Achieves Sustained Increases of Circulating Endothelial Progenitor Cells in Patients Hospitalized for Decompensated Diabetes: An Observational Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Article
- Evaluation of Circulating Endothelial Progenitor Cells in Abdominal Aortic Aneurysms after Endovascular Aneurysm Repair.International journal of stem cells · 2022Article
- Endothelial Progenitor Cells in Coronary Artery Disease: From Bench to Bedside.Stem cells translational medicine · 2022Review
- Microarray meta-analysis reveals IL6 and p38β/MAPK11 as potential targets of hsa-miR-124 in endothelial progenitor cells: Implications for stent re-endothelization in diabetic patients.Frontiers in cardiovascular medicine · 2022Article
- Unraveling the potential of endothelial progenitor cells as a treatment following ischemic stroke.Frontiers in neurology · 2022Review
- Assessment of Serum Neopterin as a Biomarker in Peripheral Artery Disease.Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 1 institution in 1 country.
Funding
Abstract
rationalePeripheral arterial disease (PAD) is a clinical manifestation of extracoronary atherosclerosis. Despite sharing the same risk factors, only 20% to 30% of patients with coronary artery disease (CAD) develop PAD. Decline in the number of bone marrow-derived circulating progenitor cells (PCs) is thought to contribute to the pathogenesis of atherosclerosis. Whether specific changes in PCs differentiate patients with both PAD and CAD from those with CAD alone is unknown.
objectiveDetermine whether differences exist in PCs counts of CAD patients with and without known PAD. METHODS AND
results1497 patients (mean age: 65 years; 62% men) with known CAD were identified in the Emory Cardiovascular Biobank. Presence of PAD (n=308) was determined by history, review of medical records, or imaging and was classified as carotid (53%), lower extremity (41%), upper extremity (3%), and aortic disease (33%). Circulating PCs were enumerated by flow cytometry. Patients with CAD and PAD had significantly lower PC counts compared with those with only CAD. In multivariable analysis, a 50% decrease in cluster of differentiation 34 (CD34+) or CD34+/vascular endothelial growth factor receptor-2 (VEGFR2+) counts was associated with a 31% (P=0.032) and 183% (P=0.002) increase in the odds of having PAD, respectively. CD34+ and CD34+/VEGFR2+ counts significantly improved risk prediction metrics for prevalent PAD. Low CD34+/VEGFR2+ counts were associated with a 1.40-fold (95% confidence interval, 1.03-1.91) and a 1.64-fold (95% confidence interval, 1.07-2.50) increases in the risk of mortality and PAD-related events, respectively.
conclusionsPAD is associated with low CD34+ and CD34+/VEGFR2+ PC counts. Whether low PC counts are useful in screening for PAD needs to be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.